Osteogenic activity of vanadyl(IV)–ascorbate complex: evaluation of its mechanism of action by Cortizo, Ana María et al.
The International Journal of Biochemistry & Cell Biology 38 (2006) 1171–1180
Osteogenic activity of vanadyl(IV)–ascorbate complex:
Evaluation of its mechanism of action
Ana M. Cortizo a,∗, M. Silvina Molinuevo a,
Daniel A. Barrio a, Liliana Bruzzone b
a Ca´tedra de Bioquı´mica Patolo´gica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata,
47 y 115, 1900 La Plata, Argentina
b Divisio´n Quı´mica Analı´tica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata,
47 y 115, 1900 La Plata, Argentina
Received 24 June 2005; received in revised form 16 November 2005; accepted 11 December 2005
Available online 9 January 2006
Abstract
We have previously shown that different vanadium(IV) complexes regulate osteoblastic growth. Since vanadium compounds are
accumulated in vivo in bone, they may affect bone turnover. The development of vanadium complexes with different ligands could
be an alternative strategy of use in skeletal tissue engineering. In this study, we have investigated the osteogenic properties of a
vanadyl(IV)–ascorbate (VOAsc) complex, as well as its possible mechanisms of action, on two osteoblastic cell lines in culture.
VOAsc (2.5–25mM) significantly stimulated osteoblastic proliferation (113–125% basal, p < 0.01) in UMR106 cells, but not in the
MC3T3E1 cell line. VOAsc (5–100mM) dose-dependently stimulated type-I collagen production (107–156% basal) in osteoblasts.
After 3 weeks of culture, 5–25mM VOAsc increased the formation of nodules of mineralization in MC3T3E1 cells (7.7–20-fold
control, p < 0.001). VOAsc (50–100mM) significantly stimulated apoptosis in both cell lines (170–230% basal, p < 0.02–0.002),
but did not affect reactive oxygen species production. The complex inhibited alkaline and neutral phosphatases from osteoblastic
extracts with semi-maximal effect at 10mM doses. VOAsc induced the activation and redistribution of P-ERK in a time- and
dose-dependent manner. Inhibitors of the mitogen activated protein kinases (MAPK) pathway (PD98059 and UO126) partially
blocked the VOAsc-enhanced osteoblastic proliferation and collagen production. In addition, wortmanin, a PI-3-K inhibitor and
type-L channel blocker nifedipine also partially abrogated these effects of VOAsc on osteoblasts. Our in vitro results suggest that
this vanadyl(IV)–ascorbate complex could be a useful pharmacological tool for bone tissue regeneration.
© 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Bone is a dynamic, highly vascularised tissue with
a unique capacity to heal and remodel throughout life
(Salgado, Coutinho, & Reis, 2004). The integrity of
the skeleton requires the coordinated regulation and
activity of bone-forming cells (osteoblasts) and bone-
resorbing cells (osteoclasts). These cells are involved inE-mail address: cortizo@biol.unlp.edu.ar (A.M. Cortizo). the turnover of bone matrix components: hydroxyapatite1357-2725/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
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and the organic part composed by glycoproteins, proteo-
glycans, sialoproteins, bone “gla” proteins. A number
of growth factors and cytokines are produced in bone
that regulate and stimulate osteogenesis and bone repairs
(Tuan, 2004). The maintenance of a balance between for-
mation and resorption results from opposing effects on
the life span of osteoblasts and osteoclasts, including
anti-apoptotic effects on the former and pro-apoptotic
effect on the latter cell type (Kousteni et al., 2002;
Manolagas, 2000). Thus, disbalance in skeletal cell activ-
ity can result in severe bone alterations. Agents used
commonly for the treatment of metabolic bone diseases,
such as parathyroid hormone and bisphosphonates, exert
their beneficial effects on bone by regulating the rate of
birth of new osteoblasts or osteoclasts or their apoptosis
(Plotkin et al., 1999).
Vanadium compounds are insulin- and growth factor-
mimetic compounds, which have been investigated by
in vitro and in vivo studies (Srivastava & Mehdi, 2005;
Thompson & Orvig, 2004). Vanadium salts stimulate
glucose consumption, decreasing high blood sugar levels
and insulin resistance of diabetic patients. In vivo studies
have been carried out to investigate vanadium biodistri-
bution. It has been shown that vanadium compounds are
mainly localized in bone, as well as in kidney, liver and
spleen after 24 h of administration. In particular, vana-
dium accumulated in the skeleton could exert specific
effects that eventually may affect bone turnover.
In this context, our group has previously
demonstrated that vanadate, vanadyl and different
adhesion (Lai et al., 2001; Manolagas, 2000; Xiao,
Jiang, Gopalakrishnan, & Franceschi, 2000). Apoptosis
is an active process of cell death that could be involved
in the regulation of bone turnover under physiological
or pathological conditions. We have recently shown
that several vanadium compounds stimulate apoptosis
by mechanisms which involve induction of intracel-
lular oxidative stress (Molinuevo, Barrio, Cortizo, &
Etcheverry, 2004). Thus, under certain conditions, vana-
dium compounds could exert toxic effect, depending
on several factors (Domingo, 2002). It is important to
evaluate the possible cytotoxic effects of new vanadium
compounds before their can be considered for use
in vivo.
Until the present, no vanadium compounds with
specific properties to induce osteogenesis have been
described. In this study, we have investigated the
osteogenic properties of a vanadyl(IV)–ascorbate
(VOAsc) complex, as well as its possible mechanisms
of action on two osteoblast-like cells in culture.
2. Materials and methods
2.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM),
trypsin–EDTA and fetal bovine serum (FBS) were
from Gibco (Life Technology, Buenos Aires, Argentina)
and tissue culture disposable material was from
Nunc (Buenos Aires, Argentina). Dihydrorhodamine123vanadium(IV) complex regulate proliferation and
differentiation of osteoblast-like cells in culture (Barrio,
Braziunas, Etcheverry, & Cortizo, 1997; Barrio,
Williams, Cortizo, & Etcheverry, 2003; Etcheverry,
Barrio, Cortizo, & Williams, 2002; Etcheverry, Williams
et al., 2002). In general, low concentrations (<25mM)
stimulate but higher doses inhibit cell proliferation and
alkaline phosphatase activity (ALP), resulting in cyto-
toxic effects on osteoblasts. Several mechanisms have
been proposed to explain the bioactivity of vanadium.
The best characterized action is its ability to stimulate
the protein tyrosine phosphorylation through the inhibi-
tion of protein tyrosine phosphatases (PTPases) (Tracey
& Gresser, 1986). As a consequence, a phosphorylation
cascade can be triggered. For example, the mitogen
activated protein kinases (MAPK) pathway and extra-
cellular signal-regulated kinase (ERK) activation have
been reported to be involved in the action of vanadium
(Barrio et al., 2003; Shechter et al., 1995). It is known
that ERK plays an important role in osteoblast function,
including the regulation of osteoblast-specific gene
expression, proliferation, matrix mineralization, and(DHR), annexin V-FITC and propidium iodide (PI) were
from Molecular Probes (Eugene, OR, USA). Goat poly-
clonal anti-ERK-1/2 antibodies, as well as a monoclonal
anti-P-ERK antibody, were from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA). All other chemicals and
reagents were obtained from commercial sources and
were of analytical grade. Vanadyl(IV)–ascorbate was
synthesized as previously described by Ferrer and char-
acterized by UV–vis and infrared spectroscopy (Ferrer,
Williams, & Baran, 1998). Stock solutions were prepared
in distilled water at room temperature and immediately
used in the different assays.
2.2. Cell culture and incubations
UMR106 rat osteosarcoma cells and MC3T3E1
mouse calvaria-derived cells were grown in DMEM con-
taining 10% FBS, 100 U/ml penicillin and 100mg/ml
streptomycin at 37 ◦C in 5% CO2 atmosphere
(McCarthy, Etcheverry, Bruzzone, & Cortizo, 1997).
Cells were seeded on 75 cm2 flasks and sub-cultured
using trypsin–EDTA and replated on multi-well plates.
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The UMR106 cell line has been shown to conserve cer-
tain characteristics of differentiated osteoblastic pheno-
type (Partridge, Alcorn, Michelangeli, Ryan, & Martin,
1983). In the case of non-transformed MC3T3E1 cells,
previous studies have demonstrated that expression of
osteoblastic markers begins after culturing the cells with
medium supplemented by 5 mM b-glycerol phosphate
(bGP) and 145mM ascorbic acid (AA) (Quarles, Yohay,
Lever, Caton, & Wenstrup, 1992). Under these culture
conditions, alkaline phosphatase activity begins to be
expressed after 10 days, and mineralisation is achieved
after extending the culture to 15 days. However, the cells
only undergo active replication during the first 5 days of
incubation.
For proliferation experiments with both cell lines, and
differentiation experiments with UMR106 osteoblasts,
cells on multi-well plates were incubated in serum-
free medium with different doses of VOAsc complex
solution (with or without inhibitors) during the peri-
ods of time indicated in the legend of figures. For
ALP and type-I collagen production experiments with
MC3T3E1 osteoblasts, cells were cultured for 2 weeks
in DMEM–10% FBS supplemented with bGP and AA,
changing the medium every other day, after which
they were serum-starved and incubated in DMEM with
different doses of VOAsc complex solution for an
additional 48 h. For mineralization experiments with
MC3T3E1 osteoblasts, cells were cultures for 2 weeks
in DMEM–10% FBS supplemented with bGP and AA
plus different concentrations of VOAsc complex solu-
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Mineralized nodules in the extracellular matrix of
MC3T3E1 osteoblasts were stained with Alizarin red S
and quantified by the measurement of the soluble cal-
cium deposition (Ueno, Kitase, Moriyama, & Inoue,
2001).
2.5. Evaluation of cell death
The mechanism of cell death induced by VOAsc was
evaluated using an annexin V-FITC/propidium iodide
assay as we have previously described (Molinuevo et
al., 2004). Early apoptotic stages were characterized by
annexin V-FITC-positive/PI-negative (V+/PI−) staining.
The cell number was determined by counting the cells
per field in eight fields per coverslips.
2.6. Determination of reactive oxygen species
(ROS) production
The possible VOAsc-induced oxidative stress in
osteoblasts was evaluated by measurement of intracel-
lular production of reactive oxygen species. ROS gener-
ation was measured by oxidation of DHR to rhodamine
as we have previously described (Cortizo, Bruzzone,
Molinuevo, & Etcheverry, 2000).
2.7. Phosphatase assay
A kinetic assay was performed using a 0.1% Triton-
X100 osteoblast extract and the fluorogenic smallion, changing this complete medium every 2 days.
.3. Cell proliferation assay
Cell proliferation was determined using the crys-
al violet bioassay as we have previously described
Molinuevo et al., 2004).
.4. Assays for osteoblast differentiation and
aturation
Osteoblastic differentiation was evaluated by two
arkers: alkaline phosphatase activity, as we have
reviously described (Molinuevo et al., 2004) and the
uantitation of type-I collagen production with a Sirius
ed-based colorimetric microssay (Tullberg-Reinert &
undt, 1999). For the latter, cells were fixed in Bouin’s
uid for 1 h, washed with water and stained with Sirius
ed dye for 1 h. The stained material was dissolved
n 0.1N sodium hydroxide and the absorbance read at
50 nm.substrate 6,8-difluoro-4-methylumbelliferyl phosphate
(DiFMUP) (Peters et al., 2003). The cell extract was
incubated with 10mM DiFMUP in phosphate buffer, pH
7.0, for 15 min. The resulting product was measured at
360/450 nm (excitation/emission wavelengths) using an
Aminco-Bowman SPF100 spectrofluorometer. Different
concentrations of VOAsc were pre-incubated with the
osteoblastic extract for 10 min before substrate addition.
2.8. Western blot analysis of P-ERK
We next evaluated the activation status of the ERK-
1/2 transduction pathway induced by VOAsc, using a
method previously described (Barrio et al., 2003). In
these experiments, osteoblastic cells growing in serum-
free medium with the addition of different concen-
trations of VOAsc, were lysated in Laemmli’s buffer
(Laemmli, Beguin, & Gujer-Kellenberger, 1979) and
the protein content was evaluated by the method of
Lowry, Rosebrough, Farr, and Randall (1951). These
lysates were heated at 100 ◦C for 3 min and aliquots
corresponding to 30mg of total protein were subjected
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to 12% SDS-PAGE. The separated proteins were then
electro-transferred to nitrocellulose membranes. After
washing and blocking, the membranes were incubated
with a monoclonal anti-P-ERK antibody, or a poly-
clonal antibody that recognizes both phosphorylated and
unphosphorylated ERK-1/2. Blots were developed using
chemioluminiscence reagents. The intensity of the spe-
cific bands was quantified by densitometry after scanning
of the photographic film. Images were analysed using the
Scion-beta 2 program.
2.9. Localization of P-ERK by immunoﬂuorescence
analysis
Cells grown on coverslips were fixed in 4%
p-formaldehyde in phosphate-buffered saline (PBS),
blocked and incubated with a monoclonal anti-P-ERK
antibody (1:200) at 4 ◦C for 16 h. After washing, a
secondary FITC–goat anti-mouse antibody (1:200) was
added for 2 h at room temperature. Coverslips were
mounted in a Vectastain mounting liquid and the dis-
tribution of the specific protein was imaged using a
Nikon-5000 fluorescence microscope and a digital cam-
era.
2.10. Stability studies
To test the stability of VOAsc solutions under the
different experimental conditions used in this work, we
used a method previously described by our group (Barrio
et al., 2003; Williams, Molinuevo, Okulik, Jubert, &
Etcheverry, 2005). The rates of the decomposition reac-
tion of VOAsc complex in water, culture medium or
glycine buffer, pH 10, were determined by measuring
the time-dependent variation of the UV–vis spectra at 25
or 37 ◦C. In order to prevent contact of the sample withFig. 1. Effect of VOAsc on cell proliferation, differentiation and mineralizatio
of VOAsc. Cell proliferation was determined by crystal violet assay after 24
phosphatase activity (B), type-I collagen production (C) after 48 h of culture
weeks of culture by calcium nodules staining with Alizarin red (D). Data rep
expressed as % basal or fold control (#p < 0.05, *p < 0.01 and **p < 0.001).n. MC3T3E1 and UMR106 cells were incubated with different doses
h of culture (A), osteoblastic differentiation was assessed by alkaline
, and matrix mineralization of MC3T3E1 cells was evaluated after 2
resent the mean ± S.E.M. of three independent experiments and are
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atmospheric oxygen, the measurements were performed
directly in the spectrophotometer cell, adequately cov-
ered with a stopped and parafilm.
2.11. Statistical analysis
Three independent experiments were run for each
experimental condition. Results are expressed as the
mean ± S.E.M. Statistical analysis of the data was per-
formed by Student’s t-test.
3. Results
3.1. Effects of VOAsc on proliferation,
differentiation and mineralization of osteoblast-like
cells
In order to investigate the effect of VOAsc on cell
proliferation and differentiation, both osteoblast-like cell
lines (MC3T3E1 and UMR106) were used. Treatment of
osteoblasts with VOAsc (2.5–100mM) for 24–48 h led
to a biphasic effect on cell proliferation as determined
by the crystal violet bioassay. Fig. 1A shows that low
doses of VOAsc (2.5–25mM) significantly stimulated
UMR106 osteoblast proliferation, while higher doses
did not affect (UMR106) or inhibited (MC3T3E1) cell
growth. To examine the effect of VOAsc on osteoblast
differentiation, alkaline phosphatase activity and type-I
collagen production were evaluated in both cell lines.
As can be seen in Fig. 1B, the vanadium compound
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Fig. 2. Effect of VOAsc on apoptosis. Osteoblasts were treated with
0–100mM VOAsc for 4 h. Apoptosis was assessed by annexin V/PI
staining as it was described in Section 2. Data are expressed as %
basal and represent the mean ± S.E.M. of three experiments (*p < 0.02
and **p < 0.01).
V/PI staining. Both cell lines were treated with the
vanadium compound (25–100mM) for 4 h. The results
(Fig. 2) show that 25mM concentration did not induce
cell death but higher concentrations (50–100mM) sig-
nificantly stimulated apoptosis in both cell lines. Since
these effects could be associated with induction of oxida-
tive stress, we next investigated the ROS production
after incubation with VOAsc. The vanadium compound
(25–100mM) did not affect ROS production in the
UMR106 osteoblastic cell line as evaluated by the DHR
assay (data not shown). These data suggest that the
VOAsc-induced apoptotic effect on osteoblastic cultures
is not due to induction of oxidative stress.
3.3. VOAsc inhibition of phosphatases
Because vanadate and other vanadium complexes are
potent inhibitors of different phosphatases, we investi-
gated the possible inhibitory effect of VOAsc on alkaline
and neutral phosphatases. For this purpose, an extract
of osteoblastic cells was used as source of enzyme and
incubated 10 min with the vanadium complex. When
para-nitro phenylphosphate (p-NPP) in a pH 10 buffer
was used as substrate to evaluate ALP, VOAsc had a sig-
nificant inhibitory effect with a dose-dependent pattern
(Fig. 3). Maximal inhibition occurred at 100mM concen-
tration with a half-effect at 10mM. Likewise, by using
the fluorogenic assay of DiFMUP substrate under neutral
conditions to evaluate PTPases, an inhibitory effect was5–25mM) inhibited ALP in UMR106 cells although
t did not affect this marker of differentiation in the
C3T3E1 pre-osteoblasts. Under similar conditions,
OAsc dose-dependently stimulated the formation of
collagenous matrix both in the UMR106 and the
C3T3E1 cell line (Fig. 1C). Furthermore, the effect
f this vanadium complex on the ability of MC3T3E1
ells to mineralize the matrix was assessed after 2 weeks
f culture in the presence of b-glycerol phosphate and
scorbic acid. Fig. 1D shows that VOAsc markedly and
ose-dependently stimulated calcium deposition in min-
ralized nodules as assessed by the Alizarin red S stain-
ng. These results indicate that at low doses (<25mM),
OAsc is a weak mitogen and, although it partially
nhibits ALP, its long-term exposure to osteoblastic cul-
ures (2 weeks) results in osteogenic effects.
.2. Mechanism of cell death and oxidative stress
nduced by VOAsc
To evaluate the possible effect of VOAsc on cell death,
arly apoptotic processes were analyzed by annexin-
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Fig. 3. Effect of VOAsc on phosphatase activity. UMR106 cellu-
lar extracts were incubated with p-NPP (ALP activity) or DiFMUP
(PTPases) in the presence of different concentrations of VOAsc.
Results are presented as % basal (absence of VOAsc) and are rep-
resentative of three experiments.
also observed in the range of concentrations in which
VOAsc affects cell growth and differentiation. In this
case, 50mM VOAsc induced the maximal inhibition with
a semi-maximal effect at 10mM.
3.4. Activation and subcellular re-distribution of
P-ERK induced by VOAsc
To determine the role of MAPK (an important sig-
naling intermediate of growth factor pathway) in the
osteoblastic effects of VOAsc, we assessed the phos-
phorylation status of ERK-1/2. Treatment of osteoblasts
with 1 mM VOAsc resulted in a time-dependent increase
of phosphorylated p44/42-ERK as evaluated using a
phospho-ERK-specific antibody. This effect was also
dependent on the concentration of the complex. VOAsc-
induced activation was most prominent after 1 h incuba-
tion (Fig. 4A) with a maximal phosphorylation increase
at a concentration of 1 mM (Fig. 4B). There was
no change in protein amounts of ERK as assessed
by immunoblots using anti-ERK antibodies (data not
shown).
Because phosphorylation/activation of ERK depends
on the presence of MAPK in the nucleus, we examined
whether or not VOAsc alters the subcellular distribu-
tion of P-ERK. In control UMR106 osteoblasts, P-ERK
was weakly detected in the cytoplasm with a diffuse and
punctate pattern throughout the cell body (Fig. 5). Treat-
Fig. 4. Time and dose-dependent phosphorylation of ERK induced
by VOAsc. Osteoblasts were treated with 1 mM VOAsc for different
periods of time (A) or incubated for 1 h with increasing doses of VOAsc
(B). Cells were lysated in Laemmli’s buffer and analyzed by Western
blot using an anti-P-ERK antibody. Results are expressed as % basal
and represent the mean ± S.E.M. of three independent experiments.
ment with 1 mM VOAsc stimulated P-ERK-associated
immunofluorescence after 15 min, reaching a maximum
by 30 min and persisting for 30–60 min. This time course
closely matched osteoblast P-ERK activation as detected
by Western blot. In addition, P-ERK-associated fluo-
rescence exhibited a re-distribution from the cytoplasm
to the nucleus after 15–30 min incubation with 1 mM
VOAsc. The signal diminished and the remaining P-ERK
was mainly cytoplasmic after 60 min incubation. These
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Fig. 5. VOAsc induced subcellular redistribution of P-ERK. UMR106
cells were treated with 1 mM VOAsc for different periods of time and
the P-ERK-associated inmunofluorescence was analyzed. Objective
40×.
results suggest that this vanadium complex could be reg-
ulating osteoblastic growth by the MAPK pathway.
3.5. Signal transduction pathways involved in the
osteogenic action of VOAsc
In order to investigate the relative importance of
different signal transduction pathways involved in the
VOAsc-induced osteogenic actions, the effect of variousFig. 6. Effect of different signalling pathways inhibitors on cell pro-
liferation (A) and collagen production (B) induced by VOAsc. Cell
cultures were incubated with 25mM VOAsc in the presence of nifedip-
ine, wortmanin, PD98059 and UO126 during 24 h. After this incu-
bation period, cell proliferation or type-I collagen production assays
were performed as it was described in Section 2. Data are expressed
as mean ± S.E.M. and are expressed as % basal of three independent
experiments.
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inhibitors was evaluated (Fig. 6). We found that inhibi-
tion with PD98059 or UO126 (MAPK inhibitors) com-
pletely blocked VOAsc-enhanced proliferation (Fig. 6A)
and about 50% of collagen production (Fig. 6B). In
addition, wortmanin (a PI-3-K inhibitor) and the L-type
calcium channel blocker nifedipine, also partly abolished
the effects of the vanadium complex on proliferation and
collagen production.
3.6. Stability of VOAsc complex solutions
The decomposition reactions of VOAsc were mea-
sured at 25 ◦C since the stock solutions were prepared
at room temperature, and at 37 ◦C, which is the tem-
perature for biological assays. Plots of ln A versus time
showed a linear decay of absorbance. The rate con-
stant for the decomposition of VOAsc solution in dis-
tilled water at 25 ◦C was k = 2.25 × 10−4 min−1. On the
other hand, in DMEM media at 37 ◦C, the k value was
8.8 × 10−4 min−1. These results suggest that VOAsc
is stable under our working conditions, although its
decomposition is greater in the culture media. In addi-
tion, we evaluated the stability of VOAsc complex in
glycine buffer pH 10 at 37 ◦C, the condition of the
ALP assay. The rate constant for the decomposition was
k = 0.8 × 10−4 min−1. Considering that the ALP assay
involved a short incubation period (10 min), these results
suggest that VOAsc complex solution is very stable in
the conditions of the phosphatase assay.
We have previously reported that other vanadium(IV)
compounds affected osteoblast proliferation and dif-
ferentiation in a biphasic manner (Barrio et al., 1997;
Barrio et al., 2003; Etcheverry, Barrio et al., 2002;
Etcheverry, Williams et al., 2002). For example, com-
plexes with maltol, aspirin, other anti-inflamatory com-
pounds and the sugar threalose at low doses stimulated
cell growth, but inhibited ALP-associated osteoblastic
differentiation. In addition, high concentrations and/or
long-term exposure to vanadium complexes showed
cytotoxic effect on osteoblastic cultures. Since vanadium
compounds could have potential clinical applications, it
is relevant to evaluate their possible toxicity (Domingo,
2002).
In the present study, we found that incubation with
ascorbic acid alone did not affect osteoblastic prolifer-
ation, ALP-specific activity nor type-I collagen produc-
tion (data not shown). The importance of ascorbic acid
in the process of osteoblastic differentiation and miner-
alization is well known. The osteogenic effects reported
for VOAsc were observed at doses of 2.5–25mM, which
are at least 6–60-fold lower than the ascorbic acid con-
centration used in the mineralization induction medium
(145mM). Recently, Park et al. (2004) reported that
ascorbic acid inhibited cell proliferation and induced
apoptosis in leukemia cells via hydrogen peroxide-
mediated mechanisms. These effects were detected at
concentrations of 0.25–1.0 mM, which are much higher
doses than those used in our present study. They also
observed that the same concentrations of ascorbic acid4. Discussion
In this study, we investigated the effect of a previously
synthesized and characterized vanadium(IV) complex
with ascorbic acid obtained at pH 7.0. Our present results
demonstrate that VOAsc exerts osteogenic actions on
osteoblasts in culture. Evidence for this notion is based
in several observations: (a) low doses of VOAsc act
as a weak mitogen stimulating osteoblastic prolifera-
tion, (b) although VOAsc partially inhibited ALP in the
UMR106 osteosarcoma line, it did not affect this marker
in the non-transformed MC3T3E1 cells, (c) VOAsc
dose-dependently stimulated type-I collagen production
in both cell lines and (d) after 2 weeks of culture, VOAsc
strongly induced the formation of nodules of mineraliza-
tion in MC3T3E1 cells, which is a much shorter period of
time than 3–4 weeks of culture required for mineraliza-
tion of these cells which has been previously described
(Quarles et al., 1992). Thus, this vanadium compound
not only induced growth and differentiation but also had
the potential to increase mineralization of the matrix,
which is an important osteoblastic function.had no significant effect on three ovarian cancer cell
lines, suggesting that the cytotoxic effect of ascorbic acid
was cell-type specific.
Apoptosis is an important process that controls cell
death and tissue regeneration (Steller, 1995). It has been
suggested that oxidative stress triggers signaling mecha-
nisms that finally lead to apoptosis. The same growth
factors and cytokines that stimulate osteoclast and
osteoblast development can also influence their apopto-
sis (Manolagas, 2000). In the present study, low doses of
VOAsc (<25mM) did not induce apoptosis in osteoblas-
tic cells. However, this compound effectively enhanced
apoptosis at higher concentrations (50–100mM). This
effect was apparently not associated with oxidative stress
since no increase in ROS production was detected in cells
treated with high concentrations of VOAsc, as assessed
by the DHR assay. We also evaluated the possible effect
of VOAsc on lipid peroxidation by TBARS produc-
tion, however, no effect was found in these studies on
osteoblaststic cells (unpublished data). These findings
are consistent with a non-oxidative stress mechanism
associated with the apoptotic process.
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In order to investigate the possible mechanism of
action of this vanadium complex, we assessed the sig-
naling transduction pathway of protein phosphorylation.
The ability of vanadium to inhibit different phosphatases
is well known, as is the importance of protein phos-
phorylation in the process of osteoblastic differentia-
tion (Xiao et al., 2002). For this reason, we examined
the inhibitory potency of VOAsc on PTPases (neu-
tral and alkaline activities) obtained from an UMR106
osteoblastic extract. VOAsc dose-dependently inhib-
ited both phosphatases, with a half maximum effect
observed around 10mM. These results were consis-
tent with VOAsc inhibitory potency on ALP activity in
UMR106 osteoblasts. These findings suggest that this
compound could be acting by regulation of intracellular
phosphorylation levels.
In consequence, ERK activation/phosphorylation was
then investigated as a possible target for VOAsc action.
This compound was found to enhance P-ERK in a
time-dependent manner in osteoblasts. First, P-ERK was
increased after 30–60 min incubation as observed by
Western immunoblot using a phospho-specific antibody.
Second, the translocation of P-ERK was shown to occur
from the cytoplasm to the nucleus after incubation with
1 mM VOAsc, with a similar time course. Finally, the
VOAsc stimulated osteoblastic proliferation and differ-
entiation were partially or totally blocked by PD98058 or
UO126, both inhibitors of MAPK pathway. In addition,
other signal transduction mechanisms seem to be impor-
tant in the osteogenic action of this compound, such
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showed that ascorbic acid partially stabilized a solu-
tion of vanadyl as measured by EPR signal during 6 h.
Altogether, these observations suggest that under our
working conditions the VOAsc complex solution is rel-
atively stable.
In conclusion, the vanadium(IV)-ascorbic acid com-
plex stimulates osteoblastic differentiation and mineral-
ization in a model of osteoblasts in culture, suggesting an
osteogenic activity for this compound. The mechanism
of action of this complex seems to involve the inhibi-
tion of several phosphatases and activation of the ERK
pathway. In addition, calcium and PI-3-K could also be
involved in the osteogenic potential of VOAsc. Further
in vitro and in vivo experiments need to be performed in
order to assess the possible use of VOAsc as a pharma-
cological tool for bone tissue regeneration.
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